Company ProfilePremium

HUGEL, INC.

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
HUGEL, INC. - Healthcare showcase

Year Founded & Workforce

2001

70 Employees

Industry

Healthcare

Services

Botulinum Toxin
H

HUGEL, INC. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

HUGEL, INC. Overview

Company Headquarters: Brisbane, US

Founded: 2001

Workforce: ~70

Company Working:

Hugel, Inc. is involved in manufacturing beauty/cosmetics products. The company operates through business segments that include botulinum toxin, hyaluronic acid filler, cosmetics, and medical devices. The company is directly present in all the major markets including the Americas, Europe, and Asia-Pacific. Botulax is manufactured by the company in the global botulinum toxin market and sold under the brand names of Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot. The company has two manufacturing facilities in South Korea and offers its products in more than 40 countries.

Strategy

Hugel, Inc. focuses on major aesthetics markets such as the Americas, Asia-Pacific, and Europe by providing quality products and generating maximum revenue from these markets. The company plans to collaborate with different physicians and clinics to create awareness about its products in the market.

Company Snapshot

$0.1M

Revenue

70

Employees

2001

Founded

Brisbane, US

Headquarters

SWOT Analysis

Strengths

  • Strong market presence in Asia-pacific Region
  • Strong R&D
  • Diverse portfolio

Weaknesses

  • Company’s manufacturing facilities are limited

Opportunities

  • Enhancing the product portfolio by launching products
  • Enhancing the product portfolio by launching products

Threats

  • Stringent government regulations related to import and export
  • Fluctuation in currency

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Product Offering

  • HUGEL, INC.
    • Botulinum Toxin

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 0.1 Mn in 2016 to USD 0.2 Mn in 2018.
HUGEL, INC. — By Business Segment
Series (USD Mn)201620172018
Sales0.10.20.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.